A detailed history of Point72 Hong Kong LTD transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Point72 Hong Kong LTD holds 3,175 shares of DNLI stock, worth $65,817. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,175
Holding current value
$65,817
% of portfolio
0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$20.24 - $31.58 $64,261 - $100,266
3,175 New
3,175 $64,000
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $123,435 - $183,133
4,753 New
4,753 $146,000
Q2 2022

Aug 15, 2022

SELL
$20.88 - $35.19 $24,930 - $42,016
-1,194 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$29.0 - $47.27 $3,625 - $5,908
-125 Reduced 9.48%
1,194 $38,000
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $17,887 - $23,108
420 Added 46.72%
1,319 $59,000
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $43,583 - $70,328
899 New
899 $45,000
Q2 2020

Aug 14, 2020

SELL
$16.01 - $28.82 $1,921 - $3,458
-120 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$14.2 - $27.98 $1,704 - $3,357
120 New
120 $2,000
Q1 2018

May 15, 2018

SELL
$15.36 - $24.8 $200,340 - $323,466
-13,043 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$15.04 - $21.45 $196,166 - $279,772
13,043
13,043 $204,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.78B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.